Haleon (LON:HLN) Receives Sell Rating from Deutsche Bank Aktiengesellschaft

Haleon (LON:HLN – Get Free Report)‘s stock had its “sell” rating restated by analysts at Deutsche Bank Aktiengesellschaft in a research note issued to investors on Wednesday,Digital Look reports. They currently have a GBX 325 price target on the stock. Deutsche Bank Aktiengesellschaft’s price target suggests a potential downside of 7.35% from the company’s previous close.

HLN has been the topic of several other research reports. Royal Bank Of Canada reissued a “sector perform” rating and issued a GBX 370 price target on shares of Haleon in a research note on Thursday, April 30th. Berenberg Bank reaffirmed a “buy” rating and set a GBX 512 price objective on shares of Haleon in a research report on Thursday, April 30th. Jefferies Financial Group decreased their price objective on Haleon from GBX 450 to GBX 400 and set a “buy” rating for the company in a report on Tuesday, May 5th. Finally, JPMorgan Chase & Co. dropped their target price on Haleon from GBX 335 to GBX 315 and set an “underweight” rating on the stock in a research report on Thursday, June 25th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Haleon currently has an average rating of “Hold” and an average target price of GBX 393.67.

Get Haleon alerts:

Get Our Latest Analysis on Haleon

Haleon Stock Up 0.9%

HLN traded up GBX 3.10 during trading on Wednesday, hitting GBX 350.80. The company had a trading volume of 142,179,078 shares, compared to its average volume of 30,300,482. The company has a market capitalization of £31.04 billion, a PE ratio of 18.96, a PEG ratio of 1.49 and a beta of 0.25. The company has a quick ratio of 0.93, a current ratio of 0.92 and a debt-to-equity ratio of 52.26. Haleon has a one year low of GBX 317.80 and a one year high of GBX 416.10. The firm’s 50-day moving average price is GBX 338.29 and its 200 day moving average price is GBX 363.90.

Haleon Company Profile

(Get Free Report)

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.

Further Reading

• Five stocks we like better than Haleon
• 3 Big Banks Plan Double Digit Dividend Increases After Passing Fed Stress Test
• 3 ETFs Offering Exposure to Latin America’s Stock Market Rally
• Could Apple’s China Play Be the Answer to Its Memory Pressure Problem?
• 3 Charts That Could Change the Course of Summer Trading

Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.